Atossa: All objectives successfully met in Phase 1 study of topical Endoxifen
Atossa Genetics reported preliminary results from its Phase 1 dose escalation study of its proprietary topical Endoxifen. All objectives were successfully met: There were no clinically significant safety signals and no clinically significant adverse events in participants receiving topical Endoxifen; Topical Endoxifen was well tolerated at each dose level and for the dosing duration utilized in the study; Topical Endoxifen crossed the skin barrier when applied daily to the breast, as demonstrated by low but measurable Endoxifen blood levels detected in a dose-dependent fashion. These data demonstrate the suitability of topical endoxifen for further clinical development. Atossa expects to announce results from the oral arm of the Phase 1 study in the next 30-60 days.